FibroBiologics (FBLG) Common Equity (2022 - 2026)

FibroBiologics (FBLG) has reported Common Equity for 5 consecutive years, with $4.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 439.07% year-over-year to $4.6 million; the trailing twelve-month figure through Jun 2026 stood at $4.6 million (up 439.07% YoY), and the FY2025 full-year result was $6.2 million, up 125.08% from the prior year.
• Common Equity advanced to $4.6 million in Q2 2026 per FBLG's latest filing, from $2.6 million in the prior quarter.
• Across five years, Common Equity topped out at $100.0 million in Q1 2024 and bottomed at -$2.4 million in Q2 2024.
• Historically, Common Equity has averaged $13.7 million across 5 years, with a median of $2.7 million in 2024.
• The widest YoY moves for Common Equity: up 15549.45% in 2024, down 121.03% in 2024.
• Over 5 years, Common Equity stood at $62.5 million in 2022, then slumped by 98.0% to $1.3 million in 2023, then soared by 118.28% to $2.7 million in 2024, then jumped by 125.08% to $6.2 million in 2025, then decreased by 24.69% to $4.6 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $4.6 million, $2.6 million, and $6.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.